Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
71,240.09 +4,363.84 (+6.53%) CMC Crypto 200
1,540.72 +52.18 (+3.50%)
Standard BioTools Inc. (LAB)
Pre-market:
| Previous close | 2.5700 |
| Open | 2.7350 |
| Bid | 2.5700 x 1000 |
| Ask | 2.6000 x 1000 |
| Day's range | 2.5600 - 2.7400 |
| 52-week range | 1.5700 - 3.1600 |
| Volume | |
| Avg. volume | 2,532,409 |
| Market cap | 977.461M |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20, 2024, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan). The equity award consisted of an award of 207,832 restricted stock units (RSUs) as a material inducement to a new empl
- GlobeNewswire
Standard BioTools Reports First Quarter 2024 Financial Results
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, res
- GlobeNewswire
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while suppo
